Regulation of human Mcl-1 by a divergently-expressed antisense transcript

Area of Science:

• Molecular Biology
• Cancer Biology
• RNA Biology

Background:

• Mcl-1 (myeloid cell leukemia 1) is a key anti-apoptotic protein in the Bcl-2 family, crucial for lymphocyte function and implicated in oncogenesis.
• Mcl-1 has a short half-life, primarily regulated by miRNA and proteasomal degradation.
• Existing regulatory mechanisms do not fully explain Mcl-1 expression control.

Purpose of the Study:

• To identify novel regulatory mechanisms controlling Mcl-1 expression at the RNA level.
• To characterize the function and mechanism of a newly identified long non-coding RNA (lncRNA) affecting Mcl-1.
• To explore the therapeutic potential of targeting this regulatory pathway in cancer.

Main Methods:

• Reporter assays to confirm promoter location.
• Tetracycline-inducible system to control mcl1-AS1 expression.
• shRNA to inhibit mcl1-AS1.
• Bioinformatics analysis for RNA-RNA interactions.
• Cell viability assays (HEK293 cells).

Main Results:

• A novel lncRNA, mcl1-AS1, was identified that negatively regulates Mcl-1 expression at both mRNA and protein levels.
• The promoter for mcl1-AS1 is located within the Mcl-1 coding region, indicating a divergent transcription mechanism.
• Inducible expression of mcl1-AS1 decreased HEK293 cell viability, while its inhibition reversed drug sensitivity.
• Bioinformatics predicted direct binding of mcl1-AS1 to Mcl-1 transcripts, suggesting transcriptional regulation.

Conclusions:

• A novel bi-directional promoter and lncRNA (mcl1-AS1) regulatory axis controlling Mcl-1 expression has been identified.
• This finding provides new insights into Mcl-1 regulation beyond miRNA and proteasomal pathways.
• Targeting the mcl1-AS1/Mcl-1 interaction may offer therapeutic strategies for cancer and enhance anti-cancer T lymphocyte function.